

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on 12/10/03

Casey Hagopian

**PATENT**

**Attorney Docket No. 39750-0006P1**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application

Inventor(s): John C. Prescott, et al.

Application No.: 10/666,927

Filed: September 17, 2003

Title: Identification of Kinase Inhibitors

PATENT APPLICATION

Art Unit: Unknown

Examiner: To Be Assigned

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, along with a concise explanation of information in a foreign language, if any, except for pending U.S. applications is attached or is identified with an asterisk as having been previously cited in priority **U.S. Patent Application No.: 10/394,322, filed:03/20/2003**, pursuant to 37 C.F.R. §1.97-1.98.

*1.98(d) A copy of any patent, publication or other information listed in an information disclosure statement is not required to be provided if it was previously cited by or submitted to the office in a prior application, provided that the prior application is properly identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120.*

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.


This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☒ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- ☒ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39750-0006P1).


Respectfully submitted,

HELLER EHRMAN WHITE & MCAULIFFE LLP

Dated: December 9, 2003

By:   
Sam L. Nguyen / Reg. No. 52,496

275 Middlefield Road  
Menlo Park, CA 94025-3506  
(650) 324-7000  
Customer No. 25213

<b>INFORMATION DISCLOSURE STATEMENT</b>  PTO-1449 DEC 12 2003		ATTY. DOCKET NO. 39750-0006P1	SERIAL NO. 10/666,927				
		APPLICANT John C. Prescott, et al.					
		FILING DATE Sept. 17, 2003	GROUP: Unknown				
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	*6,335,155	1/1/02	Wells, J., et al.	435	4		
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	*WO 03/046200	6/05/03	PCT	C12Q		<input type="checkbox"/>	<input type="checkbox"/>
	*WO 02/42773	5/30/02	PCT	G01N		<input type="checkbox"/>	<input type="checkbox"/>
	*WO 03/014308	2/20/03	PCT	C12N		<input type="checkbox"/>	<input type="checkbox"/>
	*WO 03/014072	2/20/03	PCT	C07C		<input type="checkbox"/>	<input type="checkbox"/>
	*WO 00/00823	1/06/00	PCT	G01N		<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	*Erlanson, Daniel A., et al., "Site-directed ligand discovery", PNAS, 97, (17), 2000, pp. 9367-9372.						
	*Schindler, Thomas, et al., "Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase", Science, 289, 2000, pp. 1938-1942.						
	*Dudley, David T., et al., "A synthetic inhibitor of the mitogen-activated protein kinase cascade", Proc. Natl. Acad. Sci. USA, 92, 1995, pp. 7686-7689.						
	*Sebolt-Leopold, Judith S., et al., "Blockade of the MAP kinase pathway suppresses growth of colon tumors <i>in vivo</i> ", Nature Medicine, 5, (7), 1999, pp. 810-816.						
	*Sebolt-Leopold, Judith, et al., "Development of anticancer drugs targeting the MAP kinase pathway", Oncogene, 19, 2000, pp. 6594-6599.						
	*Pargellis, Christopher, et al., "Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site", Nature Structural Biology, 9, (4), 2002, pp. 268-272.						
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>			<b>ATTY. DOCKET NO.</b> 39750-0006P1		<b>SERIAL NO.</b> 10/666,927		
<b>APPLICANT</b> John C. Prescott, et al.							
<b>FILING DATE</b> Sept. 17, 2003					<b>GROUP:</b> Unknown		
<b>U.S. PATENT DOCUMENTS</b>							
<b>EXAMINER'S INITIALS</b>	<b>PATENT NO.</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>FILING DATE</b>	
<b>FOREIGN PATENT DOCUMENTS</b>							
<b>EXAMINER'S INITIALS</b>	<b>PATENT NO.</b>	<b>DATE</b>	<b>COUNTRY</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>TRANSLATION</b>	
						<b>YES</b>	<b>NO</b>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	*Huse, Morgan, et al., "The Conformational Plasticity of Protein Kinases", Cell, 109, 2002, pp. 275-282.						
	*Regan, John, et al., "Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate", Journal of Medical Chemistry, 45, (14), 2002, pp. 2994-3008.						
	*Taylor, Susan S., et al., "Protein kinase inhibition: natural and synthetic variations on a theme", Current Opinion in Chemical Biology, 1, 1997, pp. 219-226.						
	*Johnson, Louise N., et al., "Structural Basis for Control by Phosphorylation", Chemical Reviews, 101, (8), 2001, pp. 2209-2242.						
	*Dancey, Janet, et al., "Issues and Progress with Protein Kinase Inhibitors for Cancer Treatment", Nature Reviews-Drug Discovery, 2, 2003, pp. 296-313.						
	*Cohen, Philip, "Protein kinases-the major drug targets of the twenty-first century?", Nature Reviews-Drug Discovery, 1, 2002, pp. 309-315.						
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.